메뉴 건너뛰기




Volumn 2, Issue 2, 2010, Pages 955-969

Systemic therapy of non-resectable metastatic melanoma

Author keywords

Chemotherapy; Melanoma; Metastatic; Small molecules; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; BLEOMYCIN; CANVAXIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; HYDROXYUREA; INTERLEUKIN 2; IPILIMUMAB; LOMUSTINE; MELANOMA VACCINE; NITROSOUREA; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; TICILIMUMAB; TREOSULFAN; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; VINDESINE;

EID: 79952269662     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers2020955     Document Type: Review
Times cited : (8)

References (75)
  • 1
    • 66549117524 scopus 로고    scopus 로고
    • Chemotherapeutics, chemoresistance and the management of melanoma
    • Rass, K.; Hassel, J.C. Chemotherapeutics, chemoresistance and the management of melanoma. G. Ital. Dermatol. Venereol. 2009, 144, 61-78.
    • (2009) G. Ital. Dermatol. Venereol. , vol.144 , pp. 61-78
    • Rass, K.1    Hassel, J.C.2
  • 4
    • 0034007555 scopus 로고    scopus 로고
    • Duration of survival for disseminated malignant melanoma: Results of a meta-analysis
    • Lee, M.L.; Tomsu, K.; Von Eschen, K.B. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 2000, 10, 81-92.
    • (2000) Melanoma Res , vol.10 , pp. 81-92
    • Lee, M.L.1    Tomsu, K.2    von Eschen, K.B.3
  • 5
    • 0017118272 scopus 로고
    • DTIC (NSC-45388) in malignant melanoma: A perspective
    • Comis, R.L. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat. Rep. 1976, 60, 165-176.
    • (1976) Cancer Treat Rep , vol.60 , pp. 165-176
    • Comis, R.L.1
  • 7
    • 77249135465 scopus 로고    scopus 로고
    • Treatment for metastatic malignant melanoma: Old drugs and new strategies
    • doi:10.1016/j.critevonc.2009.08.005
    • Mouawad, R.; Sebert, M.; Michels, J.; Bloch, J.; Spano, J.P.; Khayat, D. Treatment for metastatic malignant melanoma: Old drugs and new strategies. Crit. Rev. Oncol. Hematol. 2009, doi:10.1016/j.critevonc.2009.08.005.
    • (2009) Crit. Rev. Oncol. Hematol.
    • Mouawad, R.1    Sebert, M.2    Michels, J.3    Bloch, J.4    Spano, J.P.5    Khayat, D.6
  • 8
    • 0025109821 scopus 로고
    • Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases
    • Jacquillat, C.; Khayat, D.; Banzet, P.; Weil, M.; Fumoleau, P.; Avril, M.F.; Namer, M.; Bonneterre, J.; Kerbrat, P.; Bonerandi, J.J.; et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66, 1873-1878.
    • (1990) Cancer , vol.66 , pp. 1873-1878
    • Jacquillat, C.1    Khayat, D.2    Banzet, P.3    Weil, M.4    Fumoleau, P.5    Avril, M.F.6    Namer, M.7    Bonneterre, J.8    Kerbrat, P.9    Bonerandi, J.J.10
  • 11
    • 1642366280 scopus 로고    scopus 로고
    • Therapy of malignant melanoma at the stage of distant metastasis
    • Garbe, C.; Eigentler, T.K. Therapy of malignant melanoma at the stage of distant metastasis. Hautarzt 2004, 55, 195-213.
    • (2004) Hautarzt , vol.55 , pp. 195-213
    • Garbe, C.1    Eigentler, T.K.2
  • 12
    • 0024448792 scopus 로고
    • A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma
    • Legha, S.S.; Ring, S.; Papadopoulos, N.; Plager, C.; Chawla, S.; Benjamin, R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989, 64, 2024-2029.
    • (1989) Cancer , vol.64 , pp. 2024-2029
    • Legha, S.S.1    Ring, S.2    Papadopoulos, N.3    Plager, C.4    Chawla, S.5    Benjamin, R.6
  • 13
    • 0000022334 scopus 로고
    • Cisplatin, vinblastine and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: Preleminary results of a phase II Cancer Community Oncology Program (CCOP) Trial
    • Buzaid, A.C.; Legha, S.S.; Winn, R.; Belt, R.; Pollock, T.; Wiseman, C.; Ensign, L.G. Cisplatin, vinblastine and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma: preleminary results of a phase II Cancer Community Oncology Program (CCOP) Trial. J. Clin. Oncol. 1993, 12, 389a.
    • (1993) J. Clin. Oncol. , vol.12
    • Buzaid, A.C.1    Legha, S.S.2    Winn, R.3    Belt, R.4    Pollock, T.5    Wiseman, C.6    Ensign, L.G.7
  • 16
    • 33749364367 scopus 로고    scopus 로고
    • In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group
    • Ugurel, S.; Schadendorf, D.; Pfohler, C.; Neuber, K.; Thoelke, A.; Ulrich, J.; Hauschild, A.; Spieth, K.; Kaatz, M.; Rittgen, W.; Delorme, S.; Tilgen, W.; Reinhold, U. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin. Cancer Res. 2006, 12, 5454-5463.
    • (2006) Clin. Cancer Res. , vol.12 , pp. 5454-5463
    • Ugurel, S.1    Schadendorf, D.2    Pfohler, C.3    Neuber, K.4    Thoelke, A.5    Ulrich, J.6    Hauschild, A.7    Spieth, K.8    Kaatz, M.9    Rittgen, W.10    Delorme, S.11    Tilgen, W.12    Reinhold, U.13
  • 17
    • 0035136793 scopus 로고    scopus 로고
    • Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: A meta-analysis of 3273 patients from 20 randomized trials
    • Huncharek, M.; Caubet, J.F.; McGarry, R. Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res. 2001, 11, 75-81.
    • (2001) Melanoma Res , vol.11 , pp. 75-81
    • Huncharek, M.1    Caubet, J.F.2    McGarry, R.3
  • 21
    • 0032719528 scopus 로고    scopus 로고
    • Interferon-alpha-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
    • Slaton, J.W.; Perrotte, P.; Inoue, K.; Dinney, C.P.; Fidler, I.J. Interferon-alpha-mediated downregulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 1999, 5, 2726-2734.
    • (1999) Clin. Cancer Res. , vol.5 , pp. 2726-2734
    • Slaton, J.W.1    Perrotte, P.2    Inoue, K.3    Dinney, C.P.4    Fidler, I.J.5
  • 22
    • 0031881714 scopus 로고    scopus 로고
    • Effect of IFN-alpha on tumorinfiltrating mononuclear cells and regressive changes in metastatic malignant melanoma
    • Hakansson, A.; Gustafsson, B.; Krysander, L.; Hakansson, L. Effect of IFN-alpha on tumorinfiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J. Interferon Cytokine Res. 1998, 18, 33-39.
    • (1998) J. Interferon Cytokine Res. , vol.18 , pp. 33-39
    • Hakansson, A.1    Gustafsson, B.2    Krysander, L.3    Hakansson, L.4
  • 24
    • 0029340568 scopus 로고
    • Potential uses of interferon alpha 2 as adjuvant therapy in cancer
    • Agarwala, S.S.; Kirkwood, J.M. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Ann. Surg. Oncol. 1995, 2, 365-371.
    • (1995) Ann. Surg. Oncol. , vol.2 , pp. 365-371
    • Agarwala, S.S.1    Kirkwood, J.M.2
  • 25
    • 75749151759 scopus 로고    scopus 로고
    • Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: Cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
    • Agarwala, S.S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma. Melanoma Res. 2010, 20, 1-10.
    • (2010) Melanoma Res , vol.20 , pp. 1-10
    • Agarwala, S.S.1
  • 31
    • 34548240159 scopus 로고    scopus 로고
    • Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
    • Ribas, A.; Hanson, D.C.; Noe, D.A.; Millham, R.; Guyot, D.J.; Bernstein, S.H.; Canniff, P.C.; Sharma, A.; Gomez-Navarro, J. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007, 12, 873-883.
    • (2007) Oncologist , vol.12 , pp. 873-883
    • Ribas, A.1    Hanson, D.C.2    Noe, D.A.3    Millham, R.4    Guyot, D.J.5    Bernstein, S.H.6    Canniff, P.C.7    Sharma, A.8    Gomez-Navarro, J.9
  • 33
    • 55949137090 scopus 로고    scopus 로고
    • Phase III, open-lable, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC] in patients with advanced melanoma. ASCO annual proceedings Part I
    • Abstr. LBA9011
    • Ribas, A.; Hauschild, A.; Kefford, R.; Punt, C.J.; Haanen, J.B.; Marmol, M.; Garbe, C.; Gomez-Navarro, J.; Pavlov, D.; Mars, M. Phase III, open-lable, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC] in patients with advanced melanoma. ASCO annual proceedings Part I. J. Clin. Oncol. 2008, 26, Abstr. LBA9011.
    • (2008) J. Clin. Oncol. , pp. 26
    • Ribas, A.1    Hauschild, A.2    Kefford, R.3    Punt, C.J.4    Haanen, J.B.5    Marmol, M.6    Garbe, C.7    Gomez-navarro, J.8    Pavlov, D.9    Mars, M.10
  • 34
    • 77950435681 scopus 로고    scopus 로고
    • Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. ASCO Annual proceedings Part I
    • Abstr. 9009
    • Tarhini, A.A.; Moschos, S.S.; Schlesselman, J.J.; Shope-Spotloe, J.; Demark, M.; Kirkwood, J.M. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. ASCO Annual proceedings Part I. J. Clin. Oncol. 2008, 26, Abstr. 9009.
    • (2008) J. Clin. Oncol. , pp. 26
    • Tarhini, A.A.1    Moschos, S.S.2    Schlesselman, J.J.3    Shope-Spotloe, J.4    Demark, M.5    Kirkwood, J.M.6
  • 35
    • 37049011353 scopus 로고    scopus 로고
    • Results of a phase II clinical trial of 2 doses and schedules of CP-675, 206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. ASCO Annual Meeting Proceedings Part I
    • Abstr. 3000
    • Ribas, A.; Antonia, S.; Sosman, J. Results of a phase II clinical trial of 2 doses and schedules of CP-675, 206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 2007, 25, Abstr. 3000.
    • (2007) J. Clin. Oncol. , pp. 25
    • Ribas, A.1    Antonia, S.2    Sosman, J.3
  • 36
    • 4644324025 scopus 로고    scopus 로고
    • Cancer immunotherapy: Moving beyond current vaccines
    • Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 2004, 10, 909-915.
    • (2004) Nat. Med. , vol.10 , pp. 909-915
    • Rosenberg, S.A.1    Yang, J.C.2    Restifo, N.P.3
  • 37
    • 39749186213 scopus 로고    scopus 로고
    • Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group
    • Testori, A.; Richards, J.; Whitman, E.; Mann, G.B.; Lutzky, J.; Camacho, L.; Parmiani, G.; Tosti, G.; Kirkwood, J.M.; Hoos, A.; Yuh, L.; Gupta, R.; Srivastava, P.K. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J. Clin. Oncol. 2008, 26, 955-962.
    • (2008) J. Clin. Oncol. , vol.26 , pp. 955-962
    • Testori, A.1    Richards, J.2    Whitman, E.3    Mann, G.B.4    Lutzky, J.5    Camacho, L.6    Parmiani, G.7    Tosti, G.8    Kirkwood, J.M.9    Hoos, A.10    Yuh, L.11    Gupta, R.12    Srivastava, P.K.13
  • 38
    • 0037440128 scopus 로고    scopus 로고
    • Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy
    • Chung, M.H.; Gupta, R.K.; Hsueh, E.; Essner, R.; Ye, W.; Yee, R.; Morton, D.L. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J. Clin. Oncol. 2003, 21, 313-319.
    • (2003) J. Clin. Oncol. , vol.21 , pp. 313-319
    • Chung, M.H.1    Gupta, R.K.2    Hsueh, E.3    Essner, R.4    Ye, W.5    Yee, R.6    Morton, D.L.7
  • 40
    • 0035964396 scopus 로고    scopus 로고
    • A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
    • Coulie, P.G.; Karanikas, V.; Colau, D.; Lurquin, C.; Landry, C.; Marchand, M.; Dorval, T.; Brichard, V.; Boon, T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc. Natl. Acad. Sci. USA 2001, 98, 10290-10295.
    • (2001) Proc. Natl. Acad. Sci. USA. , vol.98 , pp. 10290-10295
    • Coulie, P.G.1    Karanikas, V.2    Colau, D.3    Lurquin, C.4    Landry, C.5    Marchand, M.6    Dorval, T.7    Brichard, V.8    Boon, T.9
  • 41
    • 65649129679 scopus 로고    scopus 로고
    • Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-lable phase II study of the EORTC Melanoma Group (16032-18031). ASCO Annual Proceedings Part I
    • Abstr. 9065
    • Kruit, W.H.; Suciu, S.; Dreno, B.; Chiarion-Sileni, V.; Mortier, L.; Robert, C.; Maio, M.; Brichard, V.G.; Lehmann, F.; Keilholz, U. immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-lable phase II study of the EORTC Melanoma Group (16032-18031). ASCO Annual Proceedings Part I. J. Clin. Oncol. 2008, 26, Abstr. 9065.
    • (2008) J. Clin. Oncol. , pp. 26
    • Kruit, W.H.1    Suciu, S.2    Dreno, B.3    Chiarion-Sileni, V.4    Mortier, L.5    Robert, C.6    Maio, M.7    Brichard, V.G.8    Lehmann, F.9    Keilholz, U.10
  • 53
    • 41949133119 scopus 로고    scopus 로고
    • Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. ASCO Annual Meeting Proceedings Part I
    • June 20 Supplement
    • Kefford, R.; Millward, M.; Hersey, P.; Brady, B.; Graham, M.; Johnson, R.G.; Hannah, A.L. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 2007, 25 (18S, June 20 Supplement), 8558.
    • (2007) J. Clin. Oncol. , vol.25 , Issue.18 S , pp. 8558
    • Kefford, R.1    Millward, M.2    Hersey, P.3    Brady, B.4    Graham, M.5    Johnson, R.G.6    Hannah, A.L.7
  • 57
    • 77449135697 scopus 로고    scopus 로고
    • The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells
    • Lopez-Fauqued, M.; Gil, R.; Grueso, J.; Hernandez-Losa, J.; Pujol, A.; Moline, T.; Recio, J.A. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. Int. J. Cancer 2010, 126, 1549-1561.
    • (2010) Int. J. Cancer. , vol.126 , pp. 1549-1561
    • Lopez-Fauqued, M.1    Gil, R.2    Grueso, J.3    Hernandez-Losa, J.4    Pujol, A.5    Moline, T.6    Recio, J.A.7
  • 59
    • 51449096001 scopus 로고    scopus 로고
    • A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
    • Abstr. 3510
    • Papadopoulos, K.P.; Markman, B.; Tabernero, J.; Patnaik, A.; Heath, E.I.; DeCillis, A.; Laird, D.; Aggarwal, S.K.; Nguyen, L.; LoRusso, P.M. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. J. Clin. Oncol. 2008, 26, Abstr. 3510.
    • (2008) J. Clin. Oncol. , pp. 26
    • Papadopoulos, K.P.1    Markman, B.2    Tabernero, J.3    Patnaik, A.4    Heath, E.I.5    Decillis, A.6    Laird, D.7    Aggarwal, S.K.8    Nguyen, L.9    Lorusso, P.M.10
  • 60
    • 77952575844 scopus 로고    scopus 로고
    • Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells
    • Weber, A.; Kirejczyk, Z.; Potthoff, S.; Ploner, C.; Hacker, G. Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. Transl. Oncol. 2009, 2, 73-83.
    • (2009) Transl. Oncol. , vol.2 , pp. 73-83
    • Weber, A.1    Kirejczyk, Z.2    Potthoff, S.3    Ploner, C.4    Hacker, G.5
  • 61
    • 65949106608 scopus 로고    scopus 로고
    • Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt
    • Jiang, C.C.; Yang, F.; Thorne, R.F.; Zhu, B.K.; Hersey, P.; Zhang, X.D. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 2009, 11, 436-447.
    • (2009) Neoplasia , vol.11 , pp. 436-447
    • Jiang, C.C.1    Yang, F.2    Thorne, R.F.3    Zhu, B.K.4    Hersey, P.5    Zhang, X.D.6
  • 63
    • 79151481416 scopus 로고    scopus 로고
    • A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma
    • doi:10.1007/s10637-009-9333-6
    • Lewis, K.D.; Samlowski, W.; Ward, J.; Catlett, J.; Cranmer, L.; Kirkwood, J.; Lawson, D.; Whitman, E.; Gonzalez, R. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest. New Drugs 2009, doi:10.1007/s10637-009-9333-6.
    • (2009) Invest. New Drugs.
    • Lewis, K.D.1    Samlowski, W.2    Ward, J.3    Catlett, J.4    Cranmer, L.5    Kirkwood, J.6    Lawson, D.7    Whitman, E.8    Gonzalez, R.9
  • 64
    • 58949100724 scopus 로고    scopus 로고
    • Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N047A
    • Perez, D.G.; Suman, V.J.; Fitch, T.R.; Amatruda, T., 3rd; Morton, R.F.; Jilani, S.Z.; Constantinou, C.L.; Egner, J.R.; Kottschade, L.A.; Markovic, S.N. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115, 119-127.
    • (2009) Cancer , vol.115 , pp. 119-127
    • Perez, D.G.1    Suman, V.J.2    Fitch, T.R.3    Amatruda III, T.4    Morton, R.F.5    Jilani, S.Z.6    Constantinou, C.L.7    Egner, J.R.8    Kottschade, L.A.9    Markovic, S.N.10
  • 68
    • 74949096197 scopus 로고    scopus 로고
    • A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: Toxicities, antitumor effects, and modulation of therapeutic targets
    • Su, Y.; Amiri, K.I.; Horton, L.W.; Yu, Y.; Ayers, G.D.; Koehler, E.; Kelley, M.C.; Puzanov, I.; Richmond, A.; Sosman, J.A. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin. Cancer Res. 2010, 16, 348-357.
    • (2010) Clin. Cancer Res. , vol.16 , pp. 348-357
    • Su, Y.1    Amiri, K.I.2    Horton, L.W.3    Yu, Y.4    Ayers, G.D.5    Koehler, E.6    Kelley, M.C.7    Puzanov, I.8    Richmond, A.9    Sosman, J.A.10
  • 69
    • 73949153317 scopus 로고    scopus 로고
    • Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
    • O'Day, S.; Gonzalez, R.; Lawson, D.; Weber, R.; Hutchins, L.; Anderson, C.; Haddad, J.; Kong, S.; Williams, A.; Jacobson, E. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J. Clin. Oncol. 2009, 27, 5452-5458.
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5452-5458
    • O'Day, S.1    Gonzalez, R.2    Lawson, D.3    Weber, R.4    Hutchins, L.5    Anderson, C.6    Haddad, J.7    Kong, S.8    Williams, A.9    Jacobson, E.10
  • 70
    • 33646272204 scopus 로고    scopus 로고
    • Chemotherapy and targeted therapy combinations in advanced melanoma
    • Flaherty, K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 2006, 12, 2366s-2370s.
    • (2006) Clin. Cancer Res. , vol.12
    • Flaherty, K.T.1
  • 72
    • 70449965069 scopus 로고    scopus 로고
    • PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial
    • Abstr. 9021
    • Puzanov, I.; Nathanson, K.L.; Chapman, P.B.; Xu, X.; Sosman, J.A.; McArthur, G.A.; Ribas, A.; Kim, K.B.; Grippo, J.F.; Flaherty, K.T. PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial. J. Clin. Oncol. 2009, 27(Suppl. 15s), Abstr. 9021.
    • (2009) J. Clin. Oncol. , vol.27 , Issue.SUPPL. 15s
    • Puzanov, I.1    Nathanson, K.L.2    Chapman, P.B.3    Xu, X.4    Sosman, J.A.5    McArthur, G.A.6    Ribas, A.7    Kim, K.B.8    Grippo, J.F.9    Flaherty, K.T.10
  • 73
    • 33947515933 scopus 로고    scopus 로고
    • Imatinib in melanoma: A selective treatment option based on KIT mutation status?
    • Becker, J.C.; Brocker, E.B.; Schadendorf, D.; Ugurel, S. Imatinib in melanoma: a selective treatment option based on KIT mutation status? J. Clin. Oncol. 2007, 25, e9.
    • (2007) J. Clin. Oncol. , vol.25
    • Becker, J.C.1    Brocker, E.B.2    Schadendorf, D.3    Ugurel, S.4
  • 75
    • 72049115498 scopus 로고    scopus 로고
    • KIT as a therapeutic target in melanoma
    • Garrido, M.C.; Bastian, B.C. KIT as a therapeutic target in melanoma. J. Invest Dermatol. 2010, 130, 20-27.
    • (2010) J. Invest Dermatol. , vol.130 , pp. 20-27
    • Garrido, M.C.1    Bastian, B.C.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.